Reports
Subscribe to
our newsletters!
Showing 1–20 of 37 resultsSorted by latest
-
August of 2025This competitive intelligence report about DLL3-Targeted Therapy provides a competitor evaluation in the field of product candidates targeting delta-like ligand 3 (DLL3) as of August of 2025.€ 300.00
-
August of 2025This competitive intelligence report about B7-H3 Targeted Therapy provides a competitor evaluation in the field of product candidates targeting B7-H3 (or CD276) as of August of 2025.€ 300.00
-
July of 2025This competitive intelligence report about GPC3 Targeted Therapy provides a competitor evaluation in the field of product candidates targeting glypican-3 (GPC3) as of July of 2025.€ 400.00
-
July of 2025This competitive intelligence report about Fibroblast Activation Protein (FAP) Targeted Therapy provides a competitor evaluation in the field of product candidates targeting Fibroblast Activation Protein (FAP) as of July of...€ 300.00
-
July of 2025This competitive intelligence report Folate Receptor alpha (FRα) Targeted Therapy provides a competitor evaluation in the field of product and product candidates targeting Folate Receptor alpha as of July of...€ 200.00
-
July of 2025This competitive intelligence report about TL1A Inhibitors and DR3 Antagonists provides a competitor evaluation in the field of mostly antibodies targeting TNF-like ligand 1A (TL1A) or death receptor 3 (DR3) as...€ 200.00
-
July of 2025This competitive intelligence report about TSLP Inhibitors and TSLP Receptor Antagonists provides a competitor evaluation in the field of mostly antibodies targeting Thymic Stromal Lymphopoietin (TSLP) or its receptor as of...€ 300.00
-
June of 2025Landscape analysis of Vectorized antibodies by in vivo expression of DNA or RNA regarding stakeholders, R&D pipeline, profile & composition of drug candidates and business deals from an industry perspective...€ 2600.00
-
March of 2025This Competitive Intelligence report about PSMA-Targeted Therapy & Radiodiagnostics provides a competitor evaluation in the field of imaging of PSMA-positive prostate cancer and of PSMA-targeted therapy as of March of 2025€ 500.00
-
March of 20252024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA€ 130.00
-
February of 2025Report with a landscape analysis of PD-(L)1 x VEGF(R) bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug candidates and business deals from an industry perspective...€ 2000.00
-
September of 2024Degrader-Antibody Conjugates 2024: Stakeholders, Technologies, Pipeline and Deals€ 2050.00
-
April of 2024Competitor evaluation of recombinant antibodies and cellular therapeutics targeting claudin 18.2 as of April 2024€ 430.00
-
March of 20242023 sales data of originator therapeutic proteins and antibodies, selected biosimilars and other biologic drug modalities (gene & cell therapy, RNA)€ 130.00
-
August of 2023This report provides a landscape description and analysis of discovery and development of claudin 18.2 (CLDN18.2)-targeted antibody and cell therapy candidates from an industry perspective as of August 2023Original price was: € 2150.00.€ 1720.00Current price is: € 1720.00.
-
July of 2023This report provides a competitor evaluation in the field of antibodies, proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5a receptor€ 400.00
-
March of 2023Sales data of originator therapeutic proteins and antibodies & selected biosimilar antibodies and proteins and other biologics in 2022€ 120.00
-
February of 2023This report provides a landscape description and analysis of CAR-M platform technologies and stakeholders from an industry perspective as of February 2023€ 1800.00
-
November of 2022This report provides a landscape description and analysis of discovery and development of novel drug modalities targeting RNA from an industry perspective as of November 2019.€ 2350.00
-
July of 2022This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.Original price was: € 2550.00.€ 1800.00Current price is: € 1800.00.